Gilead Sciences (GILD) Debt to Equity (2009 - 2026)
Gilead Sciences (GILD) reported Debt to Equity of $0.94 for Q1 2026, down 27.9% on a YoY basis from $1.31 in Q1 2025, and down 14.15% quarter-over-quarter from $1.1 in Q4 2025.
Gilead Sciences (GILD) Debt to Equity (2009 - 2026) Analysis & Trends
Gilead Sciences has reported Debt to Equity for 18 years, with the latest figure at $0.94 in Q1 2026.
- For the quarter ending Q1 2026, Debt to Equity fell 27.9% year-over-year to $0.94; the trailing twelve-month figure through Mar 2026 stood at $0.94 (down 27.9% YoY), and the FY2025 full-year result was $1.1, down 20.86% from the prior year.
- Debt to Equity for Q1 2026 stood at $0.94, down from $1.1 in the prior quarter.
- The five-year high for Debt to Equity was $1.44 in Q1 2024, with the low at $0.94 in Q1 2026.
- Historically, Debt to Equity has averaged $1.22 across 5 years, with a median of $1.21 in 2023.
- Annual changes were most pronounced in 2024 — Debt to Equity increased 26.36% — and 2026, when it slipped 27.9%.
- Gilead Sciences' Debt to Equity stood at $1.19 in 2022, then retreated by 7.67% to $1.1 in 2023, then advanced by 26.36% to $1.39 in 2024, then dropped by 20.86% to $1.1 in 2025, then declined by 14.15% to $0.94 in 2026.
- The last three Debt to Equity figures came in at $0.94 (Q1 2026), $1.1 (Q4 2025), and $1.16 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 1.39 |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 0.68 |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -9.70 |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 1.07 |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 6.24 |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 0.94 |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 0.72 |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 2.22 |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.94 |
| Dec 31, 2025 | 1.10 |
| Sep 30, 2025 | 1.16 |
| Jun 30, 2025 | 1.27 |
| Mar 31, 2025 | 1.31 |
| Dec 31, 2024 | 1.39 |
| Sep 30, 2024 | 1.26 |
| Jun 30, 2024 | 1.28 |
| Mar 31, 2024 | 1.44 |
| Dec 31, 2023 | 1.10 |
| Sep 30, 2023 | 1.12 |
| Jun 30, 2023 | 1.20 |
| Mar 31, 2023 | 1.21 |
| Dec 31, 2022 | 1.19 |
| Sep 30, 2022 | 1.20 |
| Jun 30, 2022 | 1.30 |
| Mar 31, 2022 | 1.32 |
| Dec 31, 2021 | 1.27 |
| Sep 30, 2021 | 1.29 |
| Jun 30, 2021 | 1.53 |